

NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

Bladder Cancer

First Guideline Development Group (GDG) meeting

18th & 19th October 2012

Board Room, NCC-C, Park House, Greyfriars Road, Cardiff

GROUP MEMBERSHIP & ACTION LIST

GDG Members	
William Turner (WT)	Robert Huddart (RH) (<i>Day 1 only</i>)
Ananya Choundhury (ACh)	Hugh Mostafid (HM)
James Catto (JC)	Ashish Chandra (ACha)
Rob Jones (RJ)	Jonathan Osborn (JO)
Ben Taylor (BT)	Pauline Bagnall (PB)
Helen Chilcott (HC)	Louise Warren (LW)
Phil Kelly (PK)	
NCC-C staff	
John Graham (JG)	Andrew Champion (AC)
Elise Hasler (EH)	Nathan Bromham (NB)
Jennifer Hilgart (JH)	Matthew Prettyjohns (MP)
Lianne Gwillim (LG)	
NICE staff & Affiliated staff	
Barbara Meredith (BM) (<i>day 1 only</i>)	Claire Turner (CT) (<i>day 1 only</i>)
Luke Hounsome (LH) (<i>day 2 only</i>)	
Apologies	
Julia Verne (JV)	

REPORT OF DISCUSSIONS AT THE MEETING

1 Welcome and apologies

JG welcomed everyone to the 1st meeting of the Bladder Cancer GDG and thanked the GDG members for volunteering for the group. Each member of the group introduced themselves and gave a background to where they are from and what they do.

Apologies for absence were received from Prof Julia Verne.

2 Declarations of interest

JG gave a brief overview of the NICE conflict of interest policy to the group and noted that some GDG members had already declared interests in their applications. These were as follows:

- HM declared that his wife has been offered a part time consulting role for a pharmaceutical
- company which may market an intravesical chemotherapy drug for bladder cancer. This interest was categorised a personal family interest, meaning that HM cannot participate in discussions on any guideline topics covering intravesical chemotherapy.
- HM declared that he was involved in the trial management group of BOXIT trial (standard treatment with or without celecoxib for transitional cell bladder cancer,

but was not involved in developing the trial protocol. Funding was received from CRUK. . This interest was categorised non-personal pecuniary specific, meaning that HM cannot participate in discussions on any guideline topics covering celecoxib. (topic F & G).

- RJ declared that he is chief investigator for the TOUCAN trial (randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin, and was involved in deciding the trial protocol. This is funded by AstraZeneca. This interest was categorised non-personal pecuniary specific, meaning that RJ cannot participate in discussions on any guideline topics covering first line chemotherapy. (topic j).
- RJ declared that he is joint chief investigator on the PLUTO trial (randomised phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive transitional cell carcinoma of the urothelium, and was involved in deciding the trial protocol. This is part funded by GSK. This interest was categorised non-personal pecuniary specific, meaning that RJ cannot participate in discussions on any guideline topics covering first line chemotherapy. (topic J).
- RH declared that he is chief investigator of BC2001 (randomised phase III study of radiotherapy with and without synchronous chemotherapy in muscle invasive bladder cancer) and was involved in designing the trial protocol, which is funded by CRUK. This interest was categorised non-personal pecuniary specific, meaning that RH cannot participate in discussions on any guideline topics covering first line chemoradiotherapy. (topic H).
- RH declared that he is chief investigator of SPARE trial (randomised trial of selective bladder preservation against radical excision in muscle invasive transitional cell carcinoma of the bladder), and was involved in designing the trial protocol. This is funded by CRUK. This interest was categorised non-personal pecuniary specific, meaning that RH cannot participate in discussions on any guideline topics covering first line chemoradiotherapy. (topic H).
- RH declared that he is chief investigator of IDEAL (image guided dose escalated adaptive bladder radiotherapy) and was involved in designing the trial protocol. This is funded by CRUK and RCR. This interest was categorised non-personal pecuniary specific, meaning that RH cannot participate in discussions on any guideline topics covering first line chemoradiotherapy. (topic H).
- RH declared that he is chief investigator of trial on hypofractionated radiotherapy in bladder cancer and IMRT for bladder cancer and was involved in designing the trial protocol. This was funded by NIHR. This interest was categorised non-personal pecuniary specific, meaning that RH cannot participate in discussions on any guideline topics covering first line chemoradiotherapy. (topic H).
- RH declared that he is co-investigator of BOXIT trial (standard treatment with or without celecoxib for transitional cell bladder cancer and was involved in developing the trial protocol and is on the trial management group. This was funded by CRUK. This interest was categorised non-personal pecuniary specific, meaning that RH cannot participate in discussions on any guideline topics covering celecoxib. (topic F & G).
- ACh declared that she received an honorarium from Pierre Fabre for attending a discussion group in August 2012 on chemotherapy for metastatic bladder cancer. This was categorised as Personal pecuniary specific cannot participate in discussions on any guideline topics covering chemotherapy for metastatic bladder cancer until August 2013 (topic J).

No new interests were declared at the meeting. The GDG were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that the necessary action can be taken.

4 Discussion

The GDG were given an introduction to NICE and its guideline development methodology.

The GDG discussed the guideline scope and the topics that will be investigated. The group then drafted and agreed a PICO question for topics A, B, C, D, F, G, J, L and M.

The GDG discussed topics which were potential priorities for economic investigation.

5 Close of meeting

JG thanked the GDG for their input to the meeting, reminded them that the next meeting would be on **Thursday 6th December 2012**, starting at 10.30am in the **Board Room, NCC-C Park House, Greyfriars Road Cardiff** and closed the meeting.